Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sarepta Therapeutics
Biotech
Sarepta, Arrowhead ink $1B-plus deal for seven programs
Sarepta is paying Arrowhead $500 million in cash, plus a $325 million equity investment, for worldwide licensing rights to seven programs.
Gabrielle Masson
Nov 26, 2024 11:18am
Regenxbio starts pivotal study for DMD gene therapy
Nov 18, 2024 2:24pm
Sarepta axes late-phase DMD drug over safety signal, FDA talks
Nov 7, 2024 7:45am
Sarepta's next DMD drug seems to get the job done in phase 2
Jan 29, 2024 10:49am
FDA's Marks overrules staff drug reviewers 'with trepidation'
Jul 27, 2023 3:05pm
Santhera offloads North American rights for DMD med to Catalyst
Jun 20, 2023 9:53am
